Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE 60 versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE 60 versus SCANLUX 300.
DIATRIZOATE-60 vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent